Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquified its entire stake in the smaller biotech ...

H.C. Wainwright stated on Thursday that Sarepta Therapeutics’ (SRPT) recent divestiture in Arrowhead (ARWR) weakened its ...

Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

Sarepta Therapeutics sells 9.3M Arrowhead shares for $174M and fulfills a $100M milestone payment. Read more here.

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

Investing.com -- Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock dropped 6% after Sarepta Therapeutics (NASDAQ:SRPT) announced it sold over 9.2 million shares of Arrowhead in a privately negotiated ...

Upon closing of the agreement in February 2025, Arrowhead received a $500 million upfront payment and $325 million through the purchase by Sarepta of Arrowhead common stock priced at $27.25 per share.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). ...

Sarepta Therapeutics, the US biotech, has sold around 9.3 million shares of Arrowhead Pharmaceuticals in a privately ...